PE20160851A1 - Formas de dosificacion farmaceuticas - Google Patents

Formas de dosificacion farmaceuticas

Info

Publication number
PE20160851A1
PE20160851A1 PE2016000773A PE2016000773A PE20160851A1 PE 20160851 A1 PE20160851 A1 PE 20160851A1 PE 2016000773 A PE2016000773 A PE 2016000773A PE 2016000773 A PE2016000773 A PE 2016000773A PE 20160851 A1 PE20160851 A1 PE 20160851A1
Authority
PE
Peru
Prior art keywords
refers
dosage forms
pharmaceutical dosage
salt
desintegrants
Prior art date
Application number
PE2016000773A
Other languages
English (en)
Inventor
Suzie Ribeiro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20160851A1 publication Critical patent/PE20160851A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ORAL QUE COMPRENDE A) UN INHIBIDOR DE LA PROTEINA QUINASA QUE ES 3-(2,6-DICLORO-3,5-DIMETOXI-FENIL)-1-{6-[4-(4-ETIL-PIPERAZIN-1-IL)-FENILAMINO]-PIRIMIDIN-4-IL}-1-METIL-UREA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO TAL COMO LA SAL MONOFOSFATO ANHIDRO; B) UNO O MAS AGLUTINANTES TAL COMO HIDROXIPROPILMETILCELULOSA; Y C) UNO O MAS DESINTEGRANTES TAL COMO POLIVINILPIRROLIDONA ENTRECRUZADA. TAMBIEN SE REFIERE A UN PROCESO DE ELABORACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS MEDIADAS POR PROTEINAS QUINASAS
PE2016000773A 2013-12-13 2014-12-11 Formas de dosificacion farmaceuticas PE20160851A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
PE20160851A1 true PE20160851A1 (es) 2016-09-14

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000773A PE20160851A1 (es) 2013-12-13 2014-12-11 Formas de dosificacion farmaceuticas

Country Status (34)

Country Link
US (3) US10278969B2 (es)
EP (2) EP3597179B1 (es)
JP (2) JP6522619B2 (es)
KR (1) KR102349893B1 (es)
CN (2) CN105813635A (es)
AR (1) AR098716A1 (es)
AU (1) AU2014362999B2 (es)
CA (1) CA2930055C (es)
CL (1) CL2016001436A1 (es)
CY (1) CY1122063T1 (es)
DK (1) DK3079667T3 (es)
EA (1) EA036288B1 (es)
EC (1) ECSP16060194A (es)
ES (1) ES2745983T3 (es)
HK (1) HK1223833A1 (es)
HR (1) HRP20191691T1 (es)
HU (1) HUE045156T2 (es)
IL (1) IL245705B (es)
LT (1) LT3079667T (es)
MA (1) MA39175A1 (es)
MX (1) MX2016007652A (es)
MY (1) MY194303A (es)
NZ (2) NZ719865A (es)
PE (1) PE20160851A1 (es)
PH (1) PH12016501039A1 (es)
PL (1) PL3079667T3 (es)
PT (1) PT3079667T (es)
RS (1) RS59270B1 (es)
SG (1) SG10202104627UA (es)
SI (1) SI3079667T1 (es)
TN (1) TN2016000207A1 (es)
TW (2) TWI800759B (es)
WO (1) WO2015087283A1 (es)
ZA (1) ZA201603064B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194303A (en) 2013-12-13 2022-11-27 Novartis Ag Pharmaceutical dosage forms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
IL303500A (en) * 2020-12-18 2023-08-01 Qed Therapeutics Inc Methods for treating achondroplasia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CA2634047C (en) 2005-12-21 2016-04-12 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
MX2013015357A (es) 2011-07-01 2014-05-22 Novartis Ag Terapia de combinacion.
CA2917667A1 (en) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
MY194303A (en) 2013-12-13 2022-11-27 Novartis Ag Pharmaceutical dosage forms
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
US10130629B2 (en) 2015-03-25 2018-11-20 Novartis Ag Pharmaceutical combinations
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS

Also Published As

Publication number Publication date
WO2015087283A1 (en) 2015-06-18
NZ760002A (en) 2022-07-29
CN105813635A (zh) 2016-07-27
HK1223833A1 (zh) 2017-08-11
JP2017502941A (ja) 2017-01-26
EA036288B1 (ru) 2020-10-22
KR20160096093A (ko) 2016-08-12
SI3079667T1 (sl) 2019-10-30
AU2014362999B2 (en) 2017-10-12
TN2016000207A1 (en) 2017-10-06
SG10202104627UA (en) 2021-06-29
KR102349893B1 (ko) 2022-01-10
PL3079667T3 (pl) 2020-02-28
IL245705B (en) 2021-05-31
US11160804B2 (en) 2021-11-02
HUE045156T2 (hu) 2019-12-30
CA2930055C (en) 2023-07-04
DK3079667T3 (da) 2019-09-09
AU2014362999A1 (en) 2016-05-26
JP6804585B2 (ja) 2020-12-23
PH12016501039A1 (en) 2016-07-04
MA39175A1 (fr) 2017-10-31
ZA201603064B (en) 2017-07-26
US20200054632A1 (en) 2020-02-20
HRP20191691T1 (hr) 2019-12-27
ECSP16060194A (es) 2019-07-31
NZ719865A (en) 2022-07-29
TWI721938B (zh) 2021-03-21
TWI800759B (zh) 2023-05-01
IL245705A0 (en) 2016-07-31
TW201605494A (zh) 2016-02-16
CY1122063T1 (el) 2020-11-25
EP3597179A1 (en) 2020-01-22
MY194303A (en) 2022-11-27
CN116942629A (zh) 2023-10-27
MX2016007652A (es) 2016-10-13
PT3079667T (pt) 2019-10-10
JP6522619B2 (ja) 2019-05-29
AR098716A1 (es) 2016-06-08
EA201691231A1 (ru) 2016-10-31
EP3079667A1 (en) 2016-10-19
RS59270B1 (sr) 2019-10-31
ES2745983T3 (es) 2020-03-04
JP2019142927A (ja) 2019-08-29
US20220265651A1 (en) 2022-08-25
CA2930055A1 (en) 2015-06-18
EP3597179B1 (en) 2024-04-03
CL2016001436A1 (es) 2017-02-10
US20170007602A1 (en) 2017-01-12
TW202128137A (zh) 2021-08-01
EP3079667B1 (en) 2019-06-26
LT3079667T (lt) 2019-09-10
US10278969B2 (en) 2019-05-07

Similar Documents

Publication Publication Date Title
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
CL2015002606A1 (es) Compuesto.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
PH12017500163A1 (en) Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MD3500241T2 (ro) Terapie combinată pentru BPOC
BR112017028331A2 (pt) proteínas de fusão que se ligam a receptores fc humanos
EA033264B1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
PE20160851A1 (es) Formas de dosificacion farmaceuticas